Unity Biotechnology Company Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an α-Klotho hormone drug candidate for multiple neurology indications.
The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.
Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
Contact Details
Address: 285 East Grand Avenue South San Francisco, Delaware 94080 United States | |
| Phone | 650 416 1192 |
| Website | unitybiotechnology.com |
Stock Details
| Ticker Symbol | UNBX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US91381U2006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | President, Corporate Secretary and Director |
| Dr. Jan M. van Deursen Ph.D. | Founder |
| Alicia Tozier M.B.A. | Chief Strategy Officer |
| Dr. Federico Grossi M.D., Ph.D. | Chief Medical Officer |